{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"58"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 15 mg/kg weekly.","id":"BG000","title":"[Dose Level I] Pembrolizumab + Trebananib"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"BG001","title":"[Dose Level II] Pembrolizumab + Trebananib (Colorectal)"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"BG002","title":"[Dose Level II] Pembrolizumab + Trebananib (Ovarian)"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"BG003","title":"[Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"32.3","upperLimit":"57.0","value":"40.8"},{"groupId":"BG001","lowerLimit":"29.7","upperLimit":"74.3","value":"53.8"},{"groupId":"BG002","lowerLimit":"51.9","upperLimit":"74.6","value":"63.6"},{"groupId":"BG003","lowerLimit":"51.7","upperLimit":"62.5","value":"56.3"},{"groupId":"BG004","lowerLimit":"29.7","upperLimit":"74.6","value":"55.4"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"32"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"26"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"50"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"6"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"48"}]}],"title":"White"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"34"}]}],"title":"Performance Status 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"24"}]}],"title":"Performance Status 1"}],"description":"The Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale used to assess a patient's level of functioning and ability to perform daily activities, and to evaluate how a disease affects a patient's quality of life. It is widely used in oncology clinical trials to determine eligibility, stratify patients, and assess prognosis.\n\n0 - Fully active; able to carry on all pre-disease activities without restriction.\n\n1 - Restricted in physically strenuous activity but ambulatory and able to carry out light or sedentary work (e.g., light housework, office work).","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"Per protocol, patient characteristics will be summarized by cohort; the dose escalation and dose expansion data could be combined for patients with the same cancer type and the same treatment doses. Baseline characteristics are summarized for treated participants."}